Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
654 hedge funds and large institutions have $18B invested in Alexion Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 268 increasing their positions, 229 reducing their positions, and 93 closing their positions.
19% more funds holding in top 10
Funds holding in top 10: 16 → 19 (+3)
17% more repeat investments, than reductions
Existing positions increased: 268 | Existing positions reduced: 229
8% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 93
2% less funds holding
Funds holding: 669 → 654 (-15)
18% less capital invested
Capital invested by funds: $22B → $18B (-$3.96B)
24% less call options, than puts
Call options by funds: $279M | Put options by funds: $367M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$275M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$76.1M |
| 3 |
DnB Asset Management
Oslo,
Norway
|
+$72.6M |
| 4 |
Millennium Management
New York
|
+$63M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$61.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$350M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$276M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$219M |
| 4 |
JP Morgan Chase
New York
|
-$189M |
| 5 |
Goldman Sachs
New York
|
-$173M |
ALXN Hedge Fund Activity: Q1 2020 in Review
654 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2020, worth a combined $18B — down 18% from $22B a quarter earlier.
Sellers outnumbered buyers: 93 funds closed out of ALXN and 86 opened new positions — a net loss of 7 holders — while 229 trimmed existing stakes and 268 added.
The largest buyer was Citadel Advisors, adding an estimated $275M. The largest seller was T. Rowe Price Associates, cutting an estimated $350M.
- 654 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2020, down from 669 in Q4 2019.
- Funds reported $18B of Alexion Pharmaceuticals stock for Q1 2020, down 18% quarter-over-quarter.
- 86 funds opened new Alexion Pharmaceuticals positions in Q1 2020 and 93 closed out, a net change of -7 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2020 was Citadel Advisors, an estimated $275M added.
- The largest Alexion Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $350M sold.
Based on aggregated 13F filings for Q1 2020.